natgillin/translations-raw huggingface dataset:
Clopidogrel ratiopharm is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries). 
Zdravilo Clopidogrel ratiopharm se uporablja pri odraslih za preprečevanje aterotrombotičnih dogodkov (težav, ki jih povzročajo krvni strdki in otrdelost krvnih žil).
The standard dose of Clopidogrel ratiopharm is one 75 mg tablet once a day. 
Standardni odmerek zdravila Clopidogrel ratiopharm je ena 75-miligramska tableta enkrat dnevno.
Clopidogrel ratiopharm can be started between a few days and 35 days after the attack; 
Zdravilo Clopidogrel ratiopharm se lahko začne jemati od nekaj dni po napadu do 35 dni po njem;
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel ratiopharm. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Clopidogrel ratiopharm, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Because Clopidogrel ratiopharm is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine's. 
Ker je zdravilo Clopidogrel ratiopharm generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
The CHMP concluded that, in accordance with EU requirements, Clopidogrel ratiopharm has been shown to have comparable quality and to be bioequivalent to Plavix. 
CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Clopidogrel ratiopharm primerljivo raven kakovosti kot zdravilo Plavix ter da mu je biološko enakovredno.
For more information about treatment with Clopidogrel ratiopharm, read the package leaflet (also part of the EPAR) or contact your 
Za več informacij o zdravljenju z zdravilom Clopidogrel ratiopharm preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The Committee recommended that Clopidogrel ratiopharm be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Clopidogrel ratiopharm odobri dovoljenje za promet.
Because Clopidogrel ratiopharm is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix. 
Ker je zdravilo Clopidogrel ratiopharm generično zdravilo, so bile študije z bolniki omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Plavix.
Clopidogrel ratiopharm is a ‘generic medicine'. 
Clopidogrel ratiopharm je „generično zdravilo“.
Clopidogrel ratiopharm can be started between seven days and six months after 
Zdravilo Clopidogrel ratiopharm se lahko začne jemati od sedem dni po napadu do šest mesecev po njem;
What are the benefits and risks of Clopidogrel ratiopharm? 
Kakšne so koristi in tveganja, povezani z zdravilom Clopidogrel ratiopharm?
Other information about Clopidogrel ratiopharm 
Druge informacije o zdravilu Clopidogrel ratiopharm
Clopidogrel ratiopharm is a medicine that contains the active substance clopidogrel. 
Clopidogrel ratiopharm je zdravilo, ki vsebuje zdravilno učinkovino klopidogrel.
The active substance in Clopidogrel ratiopharm, clopidogrel, is an inhibitor of platelet aggregation. 
Zdravilna učinkovina v zdravilu Clopidogrel ratiopharm, klopidogrel, je zaviralec agregacije trombocitov.
Clopidogrel ratiopharm can be given to the following groups 
Lahko se daje naslednjim skupinam
Why has Clopidogrel ratiopharm been approved? 
Zakaj je bilo zdravilo Clopidogrel ratiopharm odobreno?
The European Commission granted a marketing authorisation valid throughout the EU for Clopidogrel 
Evropska komisija je dovoljenje za promet z zdravilom Clopidogrel ratiopharm, veljavno po vsej Evropski uniji, odobrila dne 23. septembra 2009.
How has Clopidogrel ratiopharm been studied? 
Kako je bilo zdravilo Clopidogrel ratiopharm raziskano?
What is Clopidogrel ratiopharm used for? 
Za kaj se zdravilo Clopidogrel ratiopharm uporablja?
How is Clopidogrel ratiopharm used? 
Kako se zdravilo Clopidogrel ratiopharm uporablja?
Trevaclyn with food, drink and alcohol 
Zdravilo Trevaclyn skupaj s hrano, pijačo in alkoholom
• It is important to follow the advice given in section 3 How to take Trevaclyn. 
• Pomembno je, da upoštevate navodila v poglavju 3 Kako jemati zdravilo Trevaclyn.
Efficacy and safety of Trevaclyn in combination with simvastatin > 40 mg were not included in this study. 
Učinkovitosti in varnosti zdravila Trevaclyn v kombinaciji s simvastatinom > 40 mg v tej študiji niso preučevali.
It is not known if Trevaclyn will harm your unborn baby. 
Ni znano, ali Trevaclyn škoduje nerojenemu otroku.
Your doctor will decide if Trevaclyn is right for you. 
Zdravnik bo odločil, ali je zdravilo Trevaclyn primerno za vas.
MARKETING AUTHORISATION NUMBER(S) EU/1/08/458/012 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/08/458/012
What Trevaclyn is and what it is used for 
Kaj je zdravilo Trevaclyn in za kaj ga uporabljamo
Safety and effectiveness of Trevaclyn in paediatric patients under the age of 18 years have not been established. 
Varnost in učinkovitost zdravila Trevaclyn pri pediatričnih bolnikih, mlajših od 18 let, nista bili dokazani.
• Take Trevaclyn once a day, in the evening or at bedtime. 
• Zdravilo Trevaclyn vzemite enkrat na dan, zvečer ali pred spanjem.
Therefore, Trevaclyn should not be used in children and adolescents under 18 years of age. 
Zato se zdravila Trevaclyn ne sme uporabljati pri otrocih in mladostnikih, mlajših od 18 let.
When driving vehicles or operating machines, it should be taken into account that dizziness has been reported (see section 4.8). 
Pri vožnji oz. upravljanju s stroji je treba upoštevati, da so poročali o omotici (glejte poglavje 4.8).
Side effects of Trevaclyn are: 
Neželeni učinki zdravila Trevaclyn so:
The frequencies of adverse reactions are ranked according to the following: Very common (≥ 1/10), Common (≥ 1/100 to < 1/10), Uncommon (≥ 1/1,000 to < 1/100), Rare (≥ 1/10,000 to < 1/1,000), Very rare (< 1/10,000), Not known (cannot be estimated from the available data). 
Neželeni učinki so po pogostnosti razvrščeni takole: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000).
What you need to know before you take Trevaclyn 
Kaj morate vedeti, preden boste vzeli zdravilo Trevaclyn
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy should be made taking into account the benefit of breast-feeding to the child and the benefit of Trevaclyn to the woman. 
Odločiti se je treba med nadaljevanjem/prenehanjem dojenjain nadaljevanjem/prenehanjem zdravljenja, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja z zdravilom Trevaclyn za mater.
Therefore, Trevaclyn should not be used during pregnancy unless clearly necessary. 
Zato se zdravila Trevaclyn ne sme uporabljati pri nosečnicah, razen če to ni nujno.
Do not take Trevaclyn if any of the above apply to you. 
Ne vzemite zdravila Trevaclyn, če kaj od naštetega velja za vas.
What Trevaclyn is and what it is used for What you need to know before you take Trevaclyn How to take Trevaclyn 
Kaj je zdravilo Trevaclyn in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Trevaclyn Kako jemati zdravilo Trevaclyn Možni neželeni učinki
Paediatric population Trevaclyn: No studies have been performed in paediatric patients. 
Pediatrična populacija Trevaclyn: Študij pri pediatričnih bolnikih niso izvedli.
Trevaclyn has not been studied in children and adolescents who are under 18 years of age. 
Zdravilo Trevaclyn ni raziskano pri otrocih in mladostnikih, mlajših od 18 let.
HDL cholesterol is often called ‘good' cholesterol because it helps keep the ‘bad' cholesterol from building up in the arteries and because it protects against heart disease. 
HDL holesterol pogosto imenujemo "dobri" holesterol, ker pomaga preprečevati kopičenje "slabega" holesterola v arterijah in ker varuje pred boleznijo srca.
Trevaclyn is not recommended in pregnancy unless clearly necessary. 
Zdravila Trevaclyn v nosečnosti ne priporočamo, razen če je nujno potrebno.
If you get dizzy, you should avoid driving or operating machines after taking Trevaclyn. 
Če postanete omotični, se med jemanjem zdravila Trevaclyn izogibajte vožnji ali upravljanju strojev.
It is not known if Trevaclyn will pass into your breast milk. 
Ni znano, ali Trevaclyn prehaja v materino mleko.
The effect on lipids was similar whether Trevaclyn was given as monotherapy or was added to ongoing statin therapy with or without ezetimibe. 
Učinek na lipide je bil podoben, naj je bilo zdravilo Trevaclyn uporabljeno v monoterapiji ali dodano že vpeljanemu statinskemu zdravljenju, z ezetimibom ali brez njega.
Other medicines and Trevaclyn 
Druga zdravila in zdravilo Trevaclyn
Clinically important elevations of CK (≥ 10 X ULN) were seen in 0.3 % of the patients treated with Trevaclyn with or without a statin (see section 4.4). 
Klinično pomembno zvišanje CK (≥ 10 x ZNM) so opazili pri 0,3 % bolnikov, ki so dobivali zdravilo Trevaclyn s statinom ali brez njega (glejte poglavje 4.4).
In an interim analysis of an ongoing clinical outcome study, an independent safety monitoring committee identified a higher than expected incidence of myopathy in Chinese patients taking Trevaclyn and simvastatin 40 mg. 
V vmesni analizi trenutno potekajoče preživetvene študije je neodvisen odbor za spremljanje varnosti odkril višjo pojavnost miopatije pri kitajskih bolnikih, ki so jemali zdravilo Trevaclyn in simvastatin 40 mg, kot je bilo pričakovano.
If you take more Trevaclyn than you should 
Če ste vzeli večji odmerek zdravila Trevaclyn, kot bi smeli
Trevaclyn is used in addition to diet and exercise in adult patients with primary hypercholesterolaemia or mixed dyslipidaemia: 
Zdravilo Trevaclyn se uporablja poleg diete in telesne vadbe pri odraslih bolnikih s primarno hiperholesterolemijo ali z mešano dislipidemijo:
PHARMACEUTICAL FORM AND CONTENTS 98 modified-release tablets. 
FARMACEVTSKA OBLIKA IN VSEBINA 98 tablet s prirejenim sproščanjem.
As with other nicotinic acid medicinal products, caution should be used when Trevaclyn is used in patients with unstable angina or in the acute phase of an MI, particularly when such patients are also receiving vasoactive medicinal products such as nitrates, calcium channel blockers, or adrenergic blocking agents. 
Tako kot velja za druga zdravila z nikotinsko kislino, je tudi pri zdravilu Trevaclyn potrebna previdnost, če ga uporabljate pri bolnikih z nestabilno angino pektoris ali med akutno fazo MI, zlasti kadar takšni bolniki dobivajo tudi vazoaktivna zdravila, kot so nitrati, zaviralci kalcijevih kanalov ali adrenergični zaviralci.
INFORMATION IN BRAILLE Trevaclyn 
PODATKI V BRAILLOVI PISAVI Trevaclyn
Trevaclyn should be used with caution in patients who consume substantial quantities of alcohol and/or have a past history of liver disease. 
Zdravilo Trevaclyn morate previdno uporabljati pri bolnikih, ki uživajo velike količine alkohola in/ali imajo anamnezo bolezni jeter.
Trevaclyn is used in addition to diet 
Zdravilo Trevaclyn se uporablja poleg diete za:
If you stop taking Trevaclyn Do not stop taking Trevaclyn without talking to your doctor. 
Ne nehajte jemati zdravila Trevaclyn, ne da bi se posvetovali s svojim zdravnikom.
It should be used with caution in patients with renal insufficiency, because nicotinic acid and its metabolites are primarily excreted by the kidneys (see sections 4.3, 4.4 and 5.2). 
Previdno ga morate uporabljati pri bolnikih z ledvično insuficienco, kajti nikotinska kislina in njeni presnovki se izločajo predvsem skozi ledvice (glejte poglavja 4.3, 4.4 in 5.2.)
Trevaclyn contains nicotinic acid, which at therapeutic doses is a lipid-modifying agent, and laropiprant, a potent, selective antagonist of the prostaglandin D2 (PGD2) receptor subtype 1 (DP1). 
Zdravilo Trevaclyn vsebuje nikotinsko kislino, ki v terapevtskih odmerkih vpliva na lipide, in laropiprant, močan, selektiven antagonist receptorja prostaglandina D2 (PGD2) podvrste 1 (DP1).
However, if you do not take Trevaclyn for 7 or more days in a row, talk to your doctor before restarting Trevaclyn. 
Če pa se zgodi, da zdravila Trevaclyn niste vzeli 7 ali več dni zapored, se pred ponovnim začetkom jemanja posvetujte z zdravnikom.
Supplements containing nicotinic acid: Vitamins or other nutritional supplements containing (≥ 50 mg/day) of nicotinic acid (or nicotinamide) have not been studied with Trevaclyn. 
Dodatki, ki vsebujejo nikotinsko kislino: Uporaba vitaminov in drugih prehranskih dopolnil, ki vsebujejo (≥ 50 mg/dan) nikotinsko kislino (ali nikotinamid) hkrati z zdravilom Trevaclyn ni raziskana.
Should an increase in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) of ≥ 3 X ULN persist, reduction of dose or withdrawal of Trevaclyn is recommended. 
Če zvišanje vrednosti alanin aminotransferaze (ALT) ali aspartat aminotransferaze (AST) na ≥ 3 x ZMN (zgornja meja normalne vrednosti) vztraja, je priporočljivo zmanjšati odmerek zdravila Trevaclyn ali pa zdravilo Trevaclyn prenehati uporabljati.
• Taking aspirin before you take Trevaclyn does not reduce your flushing more than taking Trevaclyn alone. 
• Jemanje acetilsalicilne kisline pred zaužitjem zdravila Trevaclyn ne bo bolj zmanjšalo zardevanja, kot če vzamete samo zdravilo Trevaclyn.
Trevaclyn contains a sugar called lactose. 
Trevaclyn vsebuje sladkor, imenovan laktoza.
If you forget to take Trevaclyn 
Če ste pozabili vzeti zdravilo Trevaclyn
Trevaclyn is indicated for the treatment of dyslipidaemia, particularly in adult patients with combined mixed dyslipidaemia (characterised by elevated levels of LDL-cholesterol and triglycerides and low HDL-cholesterol) and in adult patients with primary hypercholesterolaemia (heterozygous familial and non-familial). 
Zdravilo Trevaclyn je indicirano za zdravljenje dislipidemije, zlasti pri odraslih bolnikih s kombinirano mešano dislipidemijo (za katero so značilni zvišani LDL holesterol in trigliceridi in nizek HDL holesterol), in pri odraslih bolnikih s primarno hiperholesterolemijo (heterozigotno družinsko in nedružinsko).
In humans, nicotinamide is further predominantly metabolised to N-methylnicotinamide (MNA) and to N-methyl-2-pyridone-5-carboxamide (2PY). 
Pri človeku se nikotinamid nato presnovi v glavnem v N-metilnikotinamid (MNA) in N-metil-2-piridon-5-karboksamid (2PY).
The European Medicines Agency has waived the obligation to submit the results of studies with Trevaclyn in all subsets of the paediatric population in homozygous familial hypercholesterolaemia (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij z zdravilom Trevaclyn za vse skupine pediatrične populacije s homozigotno družinsko hiperholesterolemijo (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Switching from immediate-release (crystalline) nicotinic acid to Trevaclyn has not been studied. 
Prehod z nikotinske kisline s takojšnjim sproščanjem (kristalne nikotinske kisline) na zdravilo Trevaclyn ni raziskan.
If Trevaclyn is missed for less than 7 consecutive days, patients can resume therapy at the last administered dose. 
Če bolnik zdravila Trevaclyn ne vzame manj kot 7 dni zapored, ga lahko znova začne jemati v nazadnje uporabljanem odmerku.
Like other nicotinic acid medicinal products, Trevaclyn is contraindicated in patients with significant or unexplained hepatic dysfunction. 
Tako kot druga zdravila z nikotinsko kislino je tudi zdravilo Trevaclyn kontraindicirano pri bolnikih s pomembno ali nepojasnjeno motnjo delovanja jeter.
The European Medicines Agency has deferred the obligation to submit the results of studies with Trevaclyn in paediatric patients from 7-18 years old in heterozygous familial hypercholesterolaemia (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila obvezo za predložitev rezultatov študij z zdravilom Trevaclyn pri pediatričnih bolnikih s heterozigotno družinsko hiperholesterolemijo, starih od 7-18 let (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Patients receiving Trevaclyn, nicotinic acid (prolonged-released formulation), or placebo were also taking statins (29 % atorvastatin [5-80 mg], 54 % simvastatin [10-80 mg], 17 % other statins [2.5-180 mg] (pravastatin, fluvastatin, rosuvastatin, lovastatin)), of which 9 % were also taking ezetimibe [10 mg]. 
Bolniki, ki so dobivali zdravilo Trevaclyn, nikotinsko kislino (pripravek s podaljšanim sproščanjem), ali placebo, so jemali tudi statine (29 % atorvastatin [5-80 mg], 54 % simvastatin [10-80 mg], 17 % druge statine [2,5-180 mg] (pravastatin, fluvastatin, rosuvastatin, lovastatin)) in 9 % od teh jih je jemalo tudi ezetimib [10 mg].
CYP3A4 Inhibitor: Clarithromycin (a potent inhibitor of CYP3A4 and P-gp) did not have a clinically meaningful effect on the pharmacokinetics of laropiprant. 
Zaviralec CYP3A4: Klaritromicin (močan zaviralec CYP3A4 in P-gp) ni klinično pomembno vplival na farmakokinetiko laropipranta.
The tablets should be taken whole, with food, in the evening or at bedtime. 
Tablete Trevaclyn mora bolnik vzeti cele, s hrano, zvečer ali pred spanjem.
Flushing is the most common adverse reaction of Trevaclyn. 
Zardevanje je najpogostejši neželeni učinek zdravila Trevaclyn.
PARTICULARS TO APPEAR ON THE INTERMEDIATE CARTON Multi-packs of 196 (2 packs of 98 modified-release tablets) - without blue box (for PVC/Aclar blister) 
Multi pakiranje po 196 (2 zavoja po 98 tablet s prirejenim sproščanjem) - brez blue box-a (s PVC/Aclar pretisnimi omoti)
Not known: frequency cannot be estimated from the available data Additionally, the following were reported during post-marketing experience with Trevaclyn and/or other nicotinic acid products (alone and/or with certain other cholesterol-lowering medicines). 
Neznana: pogostnosti ni mogoče oceniti iz razpoložljivih podatkov Poleg tega so v obdobju trženja zdravila Trevaclyn in/ali drugih zdravil z nikotinsko kislino (samostojno in/ali skupaj z določenimi drugimi zdravili za zniževanje ravni holesterola) poročali o nenadni resni alergijski reakciji (anafilaktičnem šoku).
When Trevaclyn is co-administered with a statin, please refer to the Summary of Product Characteristics for that particular medicinal product. 
Če zdravilo Trevaclyn uporabljate skupaj s statinom, morate upoštevati Povzetek glavnih značilnosti za to zdravilo.
• Your doctor may also want you to periodically have blood tests after you start taking Trevaclyn, to check how well your liver is working and for other side effects. 
• Morda vas bo zdravnik na preiskave krvi napotil tudi med zdravljenjem z zdravilom Trevaclyn, da bo preveril delovanje vaših jeter in druge neželene učinke.
The pharmacokinetic interaction of Trevaclyn with statins has been studied only with simvastatin (see section 4.4). 
Izmed statinov, so farmakokinetične interakcije zdravila Trevaclyn raziskali samo s simvastatinom (glejte poglavje 4.4).
Your total cholesterol is made up mainly of ‘bad' (LDL) and ‘good' (HDL) cholesterol. 
Celotni holesterol v glavnem sestavljata "slabi" holesterol (LDL) in "dobri" holesterol (HDL).
• Take Trevaclyn with food. 
• Vzemite ga s hrano.
Laropiprant has been shown to be effective in reducing flushing symptoms induced by nicotinic acid. 
Pokazalo se je, da laropiprant učinkovito zmanjša simptome zardevanja, ki jih povzroča nikotinska kislina.
In the second study (16 weeks) where acetylsalicylic acid was allowed, patients taking Trevaclyn experienced significantly fewer days per week with moderate or greater flushing compared to nicotinic acid (prolonged-release formulation taken as a 12-week multi-step 500 mg to 2,000 mg titration) (p< 0.001). 
V drugi študiji (16 tednov), v kateri je bilo dovoljeno uporabljati acetilsalicilno kislino, so bolniki, ki so prejemali zdravilo Trevaclyn, doživljali zmerno ali izrazitejše zardevanje značilno manj dni na teden kot bolniki, ki so prejemali nikotinsko kislino (pripravek s podaljšanim sproščanjem, uporabljen v 12-tedenski večstopenjski titraciji od 500 mg do 2.000 mg) (p < 0,001).
EU/1/08/458/001 14 modified-release tablets EU/1/08/458/002 28 modified-release tablets EU/1/08/458/003 56 modified-release tablets EU/1/08/458/004 84 modified-release tablets EU/1/08/458/005 98 modified-release tablets EU/1/08/458/006 168 modified-release tablets EU/1/08/458/007 196 modified-release tablets EU/1/08/458/008 49 x 1 modified-release tablets EU/1/08/458/012 196 (2 packs of 98) modified-release tablets 
EU/1/08/458/001 14 tablet s prirejenim sproščanjem EU/1/08/458/002 28 tablet s prirejenim sproščanjem EU/1/08/458/003 56 tablet s prirejenim sproščanjem EU/1/08/458/004 84 tablet s prirejenim sproščanjem EU/1/08/458/005 98 tablet s prirejenim sproščanjem EU/1/08/458/006 168 tablet s prirejenim sproščanjem EU/1/08/458/007 196 tablet s prirejenim sproščanjem EU/1/08/458/008 49 x 1 tableta s prirejenim sproščanjem EU/1/08/458/012 196 (2 pakiranji po 98) tablet s prirejenim sproščanjem
HMG-CoA reductase inhibitors: When simvastatin is combined with nicotinic acid, a modest increase in AUC and Cmax of simvastatin acid (the active form of simvastatin) was observed, which may be devoid of clinical relevance. 
Zaviralci reduktaze HMG-CoA: Med uporabo simvastatina v kombinaciji z nikotinsko kislino sta se AUC in Cmax simvastatinske kisline (aktivne oblike simvastatina) zmerno zvišali, kar je lahko klinično nepomembno.
Eye disorders: Cystoid macular oedema, toxic amblyopia. 
Očesne bolezni: cistoiden edem makule, toksična ambliopija.
In clinical trials, over 5,700 patients received Trevaclyn alone or with an HMG-CoA reductase inhibitor. 
V kliničnih preskušanjih je zdravilo Trevaclyn samo ali skupaj z zaviralcem reduktaze HMG-CoA dobivalo več kot 2.500 bolnikov.
Effects of other medicinal products on laropiprant 
Učinki drugih zdravil na laropiprant
Cases of overdose have been reported; the maximum dose of Trevaclyn taken was 5,000 mg/100 mg. All patients recovered without sequelae. 
Poročali so o primerih prevelikega odmerjanja; največji zaužiti odmerek zdravila Trevaclyn je bil 5.000 mg/100 mg.
This will lower your chance of flushing (redness of the skin, feeling warm, itching, or tingling, particularly in your head, neck, chest and upper back). 
Tako bo manjša možnost, da se pojavi zardevanje (pordelost kože, občutek toplote, srbenje ali mravljinčenje, še zlasti v predelu glave, vratu, prsi in zgornjega dela hrbta).
Because nicotinic acid and its metabolites are excreted through the kidneys, Trevaclyn should be used with caution in patients with renal dysfunction. 
Nikotinska kislina in njeni presnovki se izločajo skozi ledvice, zato morate pri bolnikih z motenim delovanjem ledvic zdravilo Trevaclyn uporabljati previdno.
Use of Trevaclyn in patients with hepatic or renal insufficiency has not been studied. 
Uporaba zdravila Trevaclyn pri bolnikih z jetrno ali ledvično insuficienco ni raziskana.
Contents of the pack and other information 
Shranjevanje zdravila Trevaclyn Vsebina pakiranja in dodatne informacije
In three large clinical trials measuring patient-reported flushing symptoms, patients taking Trevaclyn experienced less flushing than those taking nicotinic acid (prolonged-release formulations). 
V treh velikih kliničnih preskušanjih, v katerih so ugotavljali simptome zardevanja po navedbi bolnikov, je bilo zardevanja manj med bolniki, ki so prejemali zdravilo Trevaclyn, kot med bolniki, ki so prejemali nikotinsko kislino (pripravek s podaljšanim sproščanjem).